COMMUNIQUÉS West-GlobeNewswire

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

20/09/2024 - 13:30

Experienced Life Sciences Executive Brings Strategic Expertise to Support Traws’ Further Transformation and Growth Director James J Marino Also to Step Down from Traws Board After a Decade of Service NEWTOWN, Pa., Sept [...]

DARZALEX® (daratumumab)-based quadruplet regimen receives positive CHMP opinion for transplant-eligible patients with newly diagnosed multiple myeloma

20/09/2024 - 13:40

Recommendation supported by findings from quadruplet therapy PERSEUS study with daratumumab subcutaneous (SC) formulation in the frontline setting Findings showed 60 percent reduction in risk of disease progression or [...]

Communiqué de presse : Le CHMP recommande l’approbation du Dupixent dans l’UE pour le traitement de l’œsophagite à éosinophiles de l’enfant à partir de 12 mois

20/09/2024 - 13:45

Le CHMP recommande l’approbation du Dupixent dans l’UE pour le traitement de l’œsophagite à éosinophiles de l’enfant à partir de 12 mois Recommandation fondée sur une étude de phase III ayant montré qu’une proportion [...]

Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old

20/09/2024 - 13:45

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly greater proportion of children on [...]

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old

20/09/2024 - 13:45

Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission compared to placebo, consistent with improvements seen in adults and adolescents [...]

Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ™

20/09/2024 - 14:00

OPUVIZ™, a biosimilar referencing Eylea 1 (aflibercept), is Samsung Bioepis and Biogen’s second ophthalmology biosimilar to be recommended for marketing authorization by the European Medicines Agency INCHEON, South [...]

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

20/09/2024 - 14:10

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted COVID-19 vaccine [...]

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC

20/09/2024 - 14:30

-Trial to focus on particularly vulnerable subset of patients, following strong clinician interest in use of the Alpha DaRT in this patient population - JERUSALEM, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical [...]

Autonomix Selected to Present at the 2024 Octane Medical Innovation Forum

20/09/2024 - 14:30

THE WOODLANDS, TX, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today [...]

Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements

20/09/2024 - 14:30

MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for [...]

Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed

20/09/2024 - 14:43

Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, [...]

Le médicament Iqirvo® (élafibranor) d’Ipsen est approuvé dans l’Union européenne comme premier nouveau traitement contre la cholangite biliaire primitive depuis près d’une décennie

20/09/2024 - 14:57

La Commission européenne accorde une autorisation de mise sur le marché conditionnelle à Iqirvo ® (élafibranor), nouveau traitement premier de sa classe thérapeutique contre la cholangite biliaire primitive (CBP), une [...]

Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade

20/09/2024 - 14:57

European Commission grants conditional marketing authorization for Iqirvo ® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver disease Approval follows positive CHMP opinion [...]

Firefly Neuroscience Advances AI-Driven BNA™ Technology in Neuroscience Drug Development after Completing Successful Research Collaborations with Takeda and Novartis

20/09/2024 - 15:00

TORONTO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain [...]

BioSyent Announces Agreement to Purchase Tibelia® (tibolone) Assets

20/09/2024 - 15:00

MISSISSAUGA, Ontario, Sept. 20, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc., has entered into an [...]

T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union

20/09/2024 - 15:00

LEXINGTON, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that [...]

Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel

20/09/2024 - 15:00

CARLSBAD, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced that on September 11, 2024, the Company received a notice from Nasdaq indicating that the [...]

MESMERIZE brings community pharmacy leaders together to explore industry’s bright future

20/09/2024 - 15:00

NEW YORK, Sept. 20, 2024 (GLOBE NEWSWIRE) -- MESMERIZE united three knowledge leaders in community pharmacy for an invigorating exchange of ideas, business strategies and patient-focused solutions. Published today, the [...]

Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024

20/09/2024 - 15:01

Hamilton, Bermuda, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic [...]